Annovis Bio, Inc. has announced its participation in the upcoming Alzheimer's Association International Conference $(AAIC)$ 2025, scheduled to take place from July 27-31 in Toronto, Canada. The company plans to present four scientific posters detailing advancements in its Alzheimer's clinical program and the pharmacokinetic characterization of its lead drug candidate, buntanetap. These presentations will cover various aspects, including the design of a Phase III study for early Alzheimer's patients, efficacy and safety results from a dual 6-month and 18-month clinical trial, and the comparative pharmacokinetic analysis of buntanetap in both its original semi-crystalline and novel crystalline forms. Additionally, the pharmacokinetic profile of buntanetap in patients with early Alzheimer's and Parkinson's diseases will be discussed. The results from these studies will be presented during the conference.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.